Literature DB >> 33456632

I/D Polymorphism Gene ACE and Risk of Preeclampsia in Women with Gestational Diabetes Mellitus.

O P Dmitrenko1, N S Karpova1, M K Nurbekov1, O V Papysheva2.   

Abstract

Preeclampsia (PE) and gestational diabetes mellitus (GDM) are the most common complications of pregnancy, which result in adverse outcomes for the mother and the fetus. GDM is regarded as a separate independent risk factor for PE development, as evidenced by a higher preeclampsia rate in gestational diabetes mellitus than in the general population. The role the endothelial cell dysfunction plays is considered to be the most reasonable one in the origin of these diseases. The activity of plasma and tissue angiotensin converting enzyme (ACE) is believed to be genetically controlled. The available data suggests that increased ACE activity due to deletion (D)/insertion (I) in the 16th intron of ACE gene, which is called ACE gene I/D polymorphism, is associated with preeclampsia and varies depending on the studied population and the geography. We did not find any literature data that estimates the influence of ACE gene I/D polymorphism on PE rate in pregnant women with GDM. Therefore, the present study aimed to investigate a relationship between ACE gene I/D polymorphism and preeclampsia development in the case of GDM in the Russian population. The study used the genomic DNA derived by phenol-chloroform extraction method from venous blood samples in 137 pregnant women, including samples of 74 women with GDM accompanied with PE and the blood samples of 63 women with GDM w/o preeclampsia. Genotyping of insertion/deletion in the I/D region (16 intron of АСЕ gene) was conducted by real-time PCR using the TaqMan competing probe technology. The particular features in the frequency array of alleles and genotypes of the ACE gen I/D polymorphism under review, as associated with preeclampsia development risk in pregnant women with GDM, were identified. The acquired data testify to the need to further study of ACE gene I/D region polymorphism association in a large patient sample taking into account the PE and GDM risk factors estimated in the clinical practice.
Copyright © 2020 O. P. Dmitrenko et al.

Entities:  

Year:  2020        PMID: 33456632      PMCID: PMC7785338          DOI: 10.1155/2020/8875230

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  67 in total

1.  The polymorphisms of ATOH 7, ET-1 and ACE in non-arteritic anterior ischemic optic neuropathy.

Authors:  Ting Chen; Jin Ma; Guangliang Shan; Yong Zhong
Journal:  Exp Eye Res       Date:  2018-05-21       Impact factor: 3.467

2.  Angiotensin-converting enzyme insertion-deletion polymorphism in normotensive and pre-eclamptic pregnancies.

Authors:  L Morgan; F Foster; R Hayman; S Crawshaw; P N Baker; F Broughton Pipkin; N Kalsheker
Journal:  J Hypertens       Date:  1999-06       Impact factor: 4.844

3.  Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus.

Authors:  Shannon M Heitritter; Caren G Solomon; Gary F Mitchell; Nadia Skali-Ounis; Ellen W Seely
Journal:  J Clin Endocrinol Metab       Date:  2005-04-19       Impact factor: 5.958

4.  Possible activation of the renin-angiotensin system in the feto-placental unit in preeclampsia.

Authors:  Mitsuaki Ito; Atsuo Itakura; Yasumasa Ohno; Masao Nomura; Takeshi Senga; Tetsuro Nagasaka; Shigehiko Mizutani
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

5.  Gestational diabetes and preeclampsia--similar risk factor profiles?

Authors:  Sven Schneider; Nele Freerksen; Silke Röhrig; Birgit Hoeft; Holger Maul
Journal:  Early Hum Dev       Date:  2011-09-03       Impact factor: 2.079

6.  A genetic variant of ACE increases cell survival: a new paradigm for biology and disease.

Authors:  Hamdi K Hamdi; Raquel Castellon
Journal:  Biochem Biophys Res Commun       Date:  2004-05-21       Impact factor: 3.575

7.  Angiotensin-converting enzyme gene polymorphisms, blood pressure and pulse pressure in subjects with essential hypertension in a South Sulawesi Indonesian population.

Authors:  Haerani Rasyid; Syakib Bakri; Irawan Yusuf
Journal:  Acta Med Indones       Date:  2012-10

8.  Association of angiotensin-converting enzyme intron 16 insertion/deletion and angiotensin II type 1 receptor A1166C gene polymorphisms with preeclampsia in South East of Iran.

Authors:  Saeedeh Salimi; Mojgan Mokhtari; Minoo Yaghmaei; Mohammad Jamshidi; Anoosh Naghavi
Journal:  J Biomed Biotechnol       Date:  2011-07-26

Review 9.  Current best practice in the management of hypertensive disorders in pregnancy.

Authors:  Rosemary Townsend; Patrick O'Brien; Asma Khalil
Journal:  Integr Blood Press Control       Date:  2016-07-27

10.  Correlation of angiotensin I-converting enzyme gene insertion/deletion polymorphism with rheumatic heart disease: a meta-analysis.

Authors:  Yulong Tian; Zhongchun Ge; Yuliang Xing; Yan Sun; Jie Ying
Journal:  Biosci Rep       Date:  2016-11-22       Impact factor: 3.840

View more
  4 in total

1.  Associations of CXCL12 polymorphisms with clinicopathological features in breast cancer: a case-control study.

Authors:  Shuai Lin; Yi Zheng; Meng Wang; Linghui Zhou; Yuyao Zhu; Yujiao Deng; Ying Wu; Dai Zhang; Na Li; Huafeng Kang; Zhijun Dai
Journal:  Mol Biol Rep       Date:  2022-01-25       Impact factor: 2.316

Review 2.  Gestational Diabetes Mellitus and Preeclampsia: Correlation and Influencing Factors.

Authors:  Ying Yang; Na Wu
Journal:  Front Cardiovasc Med       Date:  2022-02-16

Review 3.  A global view of hypertensive disorders and diabetes mellitus during pregnancy.

Authors:  Li Jiang; Kun Tang; Laura A Magee; Peter von Dadelszen; Alec Ekeroma; Xuan Li; Enyao Zhang; Zulfiqar A Bhutta
Journal:  Nat Rev Endocrinol       Date:  2022-09-15       Impact factor: 47.564

Review 4.  Endothelial Dysfunction in Pregnancy Complications.

Authors:  Jakub Kornacki; Paweł Gutaj; Anastasia Kalantarova; Rafał Sibiak; Maurycy Jankowski; Ewa Wender-Ozegowska
Journal:  Biomedicines       Date:  2021-11-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.